"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead

MEK162 (ARRY-162), a Novel MEK 1/2 Inhibitor, Inhibits Tumor Growth Regardless of KRas/Raf Pathway Mutations


Abstract

These data support the preclinical investigation of the effects of MEK inhibitors on apoptotic protein expression and the clinical investigation of MEK inhibitors in tumors with both wild-type and mutated Ras/Raf pathways
Poster
non-peer-reviewed

MEK162 (ARRY-162), a Novel MEK 1/2 Inhibitor, Inhibits Tumor Growth Regardless of KRas/Raf Pathway Mutations


Author Information


PDF Share